Skip to content Skip to footer
Subscribe Now
Top 20 Biopharma Deal Termination 2024
TOP 20

Top 20 Biopharma Deal Terminations of 2024

Shots: In the Biopharma industry, navigating M&A and licensing deals is challenging due to strict antitrust laws and shifting regulations. When these pressures create significant risks, nullifying or restructuring existing agreements can be the most rational and strategic response In 2024, the termination of the $4.45B deal between Adaptimmune and Genentech became a major talking…
May 14, 2025

Read more

Eisai, Biogen and BioArctic
NEWS

Eisai, Biogen and BioArctic Report the EC’s Approval of Leqembi (lecanemab) for Early Alzheimer’s Disease

Shots:The EC has approved Leqembi for the treatment of early Alzheimer’s disease in all 30 EEA statesEisai handles global development & regulatory filings for Leqembi, co-commercializing & co-promoting it with Biogen while retaining final decision-making authority. Eisai co-promotes Leqembi with Biogen in the EU (excl. Nordics) & with BioArctic in the Nordic countries, distributing it…
April 16, 2025

Read more

NEWS

Merck and Eisai Reveal Latest Data from P-III (LEAP-015) Trial of Keytruda (pembrolizumab) and Lenvima (lenvatinib) Regimen to Treat Gastroesophageal Adenocarcinoma

Shots:P-III (LEAP-015) trial assessed Keytruda + Lenvima + CT (CAPOX or mFOLFOX6 regimen) as a 1L therapy for LA/M inoperable HER2- GE adenocarcinoma pts in 2 parts (P1: safety run-in & P2: main trial). LEAP program is also assessing it in hepatocellular carcinoma & esophageal cancer P2 pts (n=880) received Keytruda (400mg, IV…
January 27, 2025

Read more

VIEWPOINTS_Michael Irizarry1_2023
VIEWPOINTS

Michael Irizarry, SVP, Clinical Research, Eisai Shared Insights on P-III Results from Clarity AD Study

Shots:Michael spoke about the P-III Clarity AD study evaluating Leqembi (lecanemab) for the treatment of mild cognitive impairment due to Alzheimer’s disease presented at CTAD 2022He also talked about Eisai’s collaboration with Biogen for the co-commercialization and co-promotion of LecanemabThe interview gives an understanding of how Biogen develops and delivers innovative therapies…
July 4, 2023

Read more

Viewpoints_Michael Irizarry
VIEWPOINTS

Michael Irizarry, SVP, Clinical Research, Eisai Shares Insights from the Clinical Data of Lecanemab Presented at AAIC

Shots:Michael talked about the new data from its Alzheimer’s pipeline at the Alzheimer’s Association International (AAIC)Michael also highlighted the study design of the P-II & P-III trial evaluating lecanemabThe interview gives an understanding of  Eisai’s human health care (hhc) concept which provides innovative products with high unmet medical needs to target diseases…
December 14, 2022

Read more

PharmaShots Interview In Conversation with Four Prominent Leaders from Eisai Where they Share Insights on New Alzheimer’s Data Presented at the Alzheimer’s & Parkinson’s Disease Conference
VIEWPOINTS

PharmaShots Interview: In Conversation with Four Prominent Leaders* from Eisai Where they Share Insights on New Alzheimer’s Data Presented at the Alzheimer’s & Parkinson’s Disease Conference

Shots:The interview provided an understanding of the data from its Alzheimer’s disease pipeline at the AD/PD ConferenceThe spokespeople also talked about the clinical trial data and key mechanisms of Eisai’s anti-amyloid compound in AD The discussion showed gave a gist of four key symposium presentations that showed how its lead candidate has the…
June 27, 2022

Read more

Load more